Short-term Fat Overfeeding on the Effects of Liver Metabolism

NCT ID: NCT05962190

Last Updated: 2023-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-15

Study Completion Date

2028-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will recruit men and women with no medical condition or relevant drug therapy that affects lipid, glucose or liver metabolism.

Purpose and design:

The investigators are asking the research question: "How does the amount and type of fat consumed, influence liver fat content, cardiac function and postprandial fatty acid and liver fat metabolism when someone is not gaining or losing body weight?"

To address this research question investigators want to undertake detail physiological studies, in a parallel dietary intervention, where individuals will have an MRI/S scans to assess liver fat, cardiac fat and cardiac function, along with a postprandial study day to assess how their metabolic response to a experimental test meal, before and then 28 days after consumption of a eucaloric, high fat intervention diet that will be either enriched in saturated or unsaturated fat.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Fat Cardiac Function Lipid Disorder Adiposity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High fat, high SFA

\~60% of total energy is from fat, of which \~45% is from SFA, \~55% is from PUFA

Group Type EXPERIMENTAL

Diet

Intervention Type BEHAVIORAL

High fat (\~60% of total energy intake) diet enriched with either SFA or UFA

High fat, high UFA

\~60% of total energy is from fat, of which \~25% is from SFA, \~75% from UFA

Group Type EXPERIMENTAL

Diet

Intervention Type BEHAVIORAL

High fat (\~60% of total energy intake) diet enriched with either SFA or UFA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diet

High fat (\~60% of total energy intake) diet enriched with either SFA or UFA

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged ≥18 or ≤65 years.
* Body Mass Index ≥19 ≤35 kg/m2
* No medical condition or relevant drug therapy that is known to affect liver or adipose tissue metabolism.
* Weight stable for the previous 3 months

Exclusion Criteria

* The participant is unwilling or unable to give informed consent for participation in the study. - Aged ≤18 or ≥65 years
* Body Mass Index ≤19 or ≥35kg/m2
* Blood haemoglobin \<135mg/dL for men and \<120mg/dL for women
* Donated (or lost) ≥250 ml of blood in the previous two months.
* On a weight loss diet or have decreased their body weight by \>5% in the previous 3 months.
* Have increased their body weight by \>5% in the previous 3 months.
* Any metabolic condition or relevant drug therapy
* Current smoker
* History of alcoholism or a greater than recommended alcohol intake (\>30 g of alcohol daily for men and \>20 g of alcohol daily for women)
* Haemorrhagic disorders
* Anticoagulant treatment
* History of albumin allergy
* Pregnant or nursing mothers
* Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months History of severe claustrophobia
* Presence of metallic implants, pacemakers, or are unwilling to remove any piercings
* History of an eating disorder or any other psychological condition that may affect the participant's ability to adhere to study intervention/experimental diets.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oxford

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leanne Hodson, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oxford Centre for Diabetes, Endocrinology and Metabolism

Oxford, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Leanne Hodson

Role: CONTACT

01865 857224

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Leanne Hodson

Role: primary

01865 857224

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

211172

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Kinetics of Metabolic Cofactors in NAFLD
NCT03838822 COMPLETED EARLY_PHASE1